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Background: Clinical algorithms for the workup of celiac disease often recommend the use of serologic assays for
initial screening, followed by duodenal biopsy for histologic confirmation. However, the majority of duodenal
biopsies submitted to pathology for “rule out celiac” are negative. The objective of this study was to determine the
underlying causes for this low diagnostic yield.
Methods: We performed a retrospective review of pathology reports from 1432 consecutive duodenal biopsies
submitted for pathologic assessment to “rule out celiac” and correlated biopsy results with results for concurrent
serologic testing for celiac autoantibodies.
Results: The majority of patients had no record of serologic testing prior to biopsy, and evidence of positive
serology results was found in only 5% of patients. Most duodenal biopsies were submitted as part of a multi-site GI
sampling strategy that included biopsies from other locations. In this context, serologic results correlated with the
likelihood of significant duodenal and non-duodenal findings, and were also helpful in evaluating patients with in-
determinate duodenal histology.
Conclusions: The presence of a positive screening test for celiac autoantibodies does not appear to be a major
driver in the decision to submit duodenal biopsies for evaluation of celiac disease, which accounts for the low
incidence of findings in these samples. In patients where celiac serology testing was performed, the results were a
good predictor of the likelihood of findings on biopsy.
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Celiac disease is one of the most common autoimmune
diseases, with an estimated prevalence of approximately
1% in various populations [1-3]. The disease is caused by
an autoimmune response to gluten which leads to pro-
gressive villous atrophy in the small bowel, resulting in
malabsorption. Gastrointestinal (GI) symptoms can be
relatively nonspecific, such as diarrhea and abdominal
pain. Systemic complications are common, and can in-
clude iron deficiency anemia and fatigue. Accurate rec-
ognition and diagnosis of celiac disease is important
because implementation of a gluten-free diet can ameli-
orate many symptoms. If left untreated, celiac disease is
associated with increased mortality in adult life from a* Correspondence: dalyt@ccf.org
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reproduction in any medium, provided the orrange of causes, including autoimmune diseases and
malignancy [4,5].
For patients with an appropriate clinical history, diag-
nostic tools for the workup of celiac disease can be di-
vided into three categories; serologic assays to measure
celiac-associated autoantibodies, genetic assays to iden-
tify HLA-DQ2 or -DQ8, and duodenal biopsy to docu-
ment the presence of villous atrophy. Although many
groups have published guidelines on the diagnosis and
management of celiac disease and the role of testing in
this process [6,7], surveys have found that there can be
significant variation in adherence to these guidelines in
different practice settings [8]. While the exact steps of
the algorithms can vary slightly depending upon the spe-
cific population being tested, most approaches recom-
mend using serologic assays either prior to duodenal
biopsy [9,10] or concurrently with biopsy in cases with a
strong clinical suspicion [11].Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 Flow chart of data analysis. Initial EMR searches for
pathology reports and serology results were performed using the
criteria described in methods. Serology totals include patients with
either pre- or post-biopsy testing.
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autoantibodies against tissue transglutaminase (tTG), dea-
midated gliadin (dGDN), and endomysial tissue (EMA).
Antibodies against native gliadin are losing popularity be-
cause of inferior performance when compared to the
newer dGDN assays [12,13]. Although most assays meas-
ure IgA antibodies against these targets, IgG versions are
also available for use in patients with IgA deficiency, a dis-
order commonly associated with celiac disease [14]. The
diagnostic characteristics of celiac serology tests have been
well-described in many populations, and in general show
analytical performance sufficient for use as a screening
test [15-18]. tTG-IgA and EMA-IgA assays have shown
the best diagnostic performance in most studies, with
pooled sensitivities of 89- 90% and specificities of 98 –
99% in a recent systematic review of the literature [16].
Recent studies have suggested that the use of serologic
testing prior to endoscopy could potentially reduce the
need for intestinal biopsy to diagnose celiac disease [19].
Given the high sensitivity and specificity of serologic
testing, one would expect to find a fairly high diagnostic
yield in duodenal biopsies for celiac disease. In a popula-
tion with a disease prevalence of 1%, a test with the char-
acteristics described above (90% Sn, 98% Sp) would have
an expected positive predictive value (PPV) of roughly
47%. However, the historical experience at our institution
has been that the majority of duodenal biopsies submitted
for “rule out celiac” are histologically normal. In an effort
to understand the causes for this discrepancy, we retro-
spectively examined the utilization of celiac serology in a
cohort of patients who had been sent for duodenal biopsy.
Methods
Case finding
An automated query was run on the pathology laboratory
information system (CoPath, Cerner Corp, Waltham MA)
to identify any biopsy submissions that contained the
words “celiac”, “gluten”, or “sprue” in the clinical data field
(which is the field completed by the ordering physician to
describe the reason for the submission). Case finding and
subsequent chart review were performed following proto-
col approval by the institutional review board of the
Cleveland Clinic Foundation. All biopsy specimens were
initially reviewed and signed out by one of twelve path-
ology staff members belonging to the subspecialty gastro-
intestinal pathology group at the Cleveland Clinic, each of
whom has fellowship training in gastrointestinal pathology
or extensive experience in the field. Only samples with
adequate material for a final report to be issued were in-
cluded in the analysis. 1465 unique patients were identi-
fied during the 6 month period covered by the study
(Figure 1). A manual review of reports eliminated 33 pa-
tients without duodenal biopsies, leaving 1432 for final re-
view. Gender ratio of this cohort was 34:66 M:F, with amedian age of 45 (IQR 24–61). Histologic findings as re-
ported by the gastrointestinal pathologist who signed out
the original specimen were classified into one of four
categories; villous atrophy consistent with celiac disease
(CD), intact villous architecture with increased intrae-
pithelial lymphocytes (IVA-IEL) [20,21], normal duode-
num, or other findings. Samples were not classified in a
graded system (such as the Marsh score). Additionally, we
examined reports to determine if biopsies were simultan-
eously submitted from sites other than the duodenum,
and what additional findings were present in those sites.
Serologic testing
An automated electronic medical record search was per-
formed to identify any celiac serology results for the
1432 patients identified above. Serologic assays included
in the search were tTG (IgA or IgG), dGDN (IgA or IgG)
and EMA (IgA only). tTG IgA and IgG antibodies were
measured using the respective QUANTA Lite h-tTG
ELISA assays (INOVA Diagnostics, San Diego, CA), which
utilize human RBC-derived tTG as the capture antigen.
dGDN IgA and IgG antibodies were measured using
QUANTA Lite Gliadin II ELISAs (INOVA Diagnostics,
Table 2 Indication for endoscopy in patients where
serologic testing was performed
Indication for endoscopy # Occurrences % Patients
Abdominal pain 260 52%
Diarrhea 99 20%
Reflux-type symptoms 91 18%
Nausea/vomiting 67 13%
Workup of celiac disease 53 11%
Weight loss 37 7%
Anemia 23 5%
GI bleeding 15 3%
Other 28 6%
Results are summarized for 504 patients where an indication was listed in the
endoscopy report. For cases with multiple indications, each indication was
listed as a separate occurrence. Only cases where celiac disease was
specifically mentioned in the endoscopy report were counted as “workup for
celiac disease”.
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capture. The EMA IgA assay was performed using an in-
direct immunoflourescent assay (INOVA Diagnostics,
San Diego, CA) with primate distal esophagus as the slide
substrate. Total IgA results were also included in the rou-
tine panel to identify patients with IgA deficiency. All tests
were performed in-house at the Cleveland Clinic as part
of routine clinical testing in accordance with manufac-
turer’s recommendations. Patients with a non-negative re-
sult for any of the four assays were classified as having
positive serology in the analyses that follow. tTG, dGDN,
and EMA antibodies were detected in 51%, 54%, and 28%
of patients with positive serologic results, respectively.
Chart review
Clinical records were reviewed for the subset of 161 pa-
tients with either positive serology or biopsy results. In
the cases reviewed the following information was noted:
previous history of celiac disease, consumption of a glu-
ten free diet, timing of the gluten free diet (before or
after biopsy/serology), response to gluten free diet, HLA
testing results, and the final clinical diagnosis. Patients
were considered to have a diagnosis of celiac disease
based on positive biopsy or serologic results in the con-
text of appropriate clinical findings (such as response to
gluten-free diet or prior history of CD). Finally, endos-
copy reports were reviewed in the patients where sero-
logic testing was performed to identify the indication for
endoscopy.
Results
During the 6 month period of the study, 1432 duodenal
biopsies were received where celiac disease was part of
the differential specified in the pathology request. Less
than one-third of these patients had evidence of celiac
serology results in the medical record, and even in pa-
tients with pre-biopsy testing the majority were sero-
logically negative (Table 1). Celiac disease was noted as
an indication for endoscopy in 11% of patients where
serologic testing was performed (Table 2). Although onlyTable 1 Serologic testing in patients sent for duodenal
biopsy
Biopsy result
N Celiac IVA Other NEG
No serology prior to biopsy 977 1.6% 6.2% 7.6% 84.5%
Pre-biopsy serology
Positive serology 68 35.3% 10.3% 2.9% 51.5%
Negative serology 387 1.0% 4.4% 8.3% 95.3%
N = total number of biopsies in each serologic category. Biopsy results refer
only to findings from the duodenal biopsy. IVA = intact villous architecture
with intra-epithelial lymphocytes. Findings consistent with celiac disease were
significantly higher in patients with positive pre-biopsy serologic results when
compared to either group (p < 0.001, Fisher’s exact test).5% (68/1432) of the study cohort had evidence of posi-
tive serologic results prior to biopsy, the likelihood of
findings consistent with CD was significantly higher in this
group when compared to patients with negative serology
or patients without serologic testing (Table 1, p < 0.001 for
both comparisons, Fisher’s exact test). The overall inci-
dence of histologic findings consistent with CD in the
entire cohort was 3% (44/1432).
To understand why such a high proportion of these bi-
opsies were sent in the absence of serologic findings, we
looked for the presence of additional biopsy locations
submitted concurrently with the duodenal biopsy. Virtu-
ally all duodenal biopsies in this study (88%) were sub-
mitted as part of a multi-site GI workup which included
biopsies from at least one other location. The most com-
mon combinations were stomach and duodenum (26%)
and stomach, esophagus, and duodenum (24%). The pres-
ence of a positive serology did seem to influence the deci-
sion to limit biopsy to the duodenum, as patients with a
positive celiac serology result had a slightly lower number
of biopsy sites (average 2.5 vs 2.9 for negative serology)
and were the most likely group to have only a single
sample submitted (Figure 2). However, even in patients
with positive serology, multiple biopsy sites were a com-
mon occurrence.
Given that serologic status correlated well with the
presence of celiac disease on biopsy, we examined the
diagnostic yield of additional biopsy sites in these patients.
We first evaluated the likelihood of significant findings in
non-duodenal sites of patients with positive celiac ser-
ology. 58% of patients with positive celiac serology had
findings noted in at least one non-duodenal site (Table 3).
Although the majority of these findings were non-specific
inflammatory changes, significant celiac-related disease
findings such as lymphocytic gastritis and colitis were
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Figure 2 Influence of serology results on number of biopsy sites. Non-duodenal biopsy sites included esophagus, stomach, ileum, and colon.
Patients were grouped according to pre-biopsy serology results as described in methods. The frequency of duodenal-only biopsy was significantly
higher in patients with positive serology than in other groups (p < 0.01, chi-squared).
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creased rate of such findings in CD patients [22,23]. Con-
versely, in patients who had duodenal sections submitted
despite having negative celiac serologic results only 14%
had abnormal histology, with the most common findings
being IVA-IEL and various presentations of non-specific
duodenitis (Table 2). Villous atrophy was noted in four
serology-negative cases, which included one case of col-
lagenous sprue and two patients with known CD being
evaluated for response to a gluten-free diet.
Finally, we identified a subset of 65 patients where ser-
ology had been ordered after the biopsy was performed.
The majority of these were patients with indeterminateTable 3 Non-celiac findings in patients with multiple biopsy s
Non-duodenal findings in patients with positive pre-biopsy serology
Finding Site N %
Chronic gastritis S 18 26%
Active esophagitis E 3 4%
Lymphocytic gastritis S 2 3%
Helicobacter pylori S 2 3%
Other gastric S 2 3%
Reflux, EE E 2 3%
Ilietis I 2 3%
Active colitis C 2 3%
Other colon C 2 3%
Lymphocytic colitis C 1 1%
Results were tabulated for 409 patients with pre-biopsy serologic results and multip
includes erosive gastritis and a gastric polyp. “Other colon” includes tubular adenom
serologic category.(IVA-IEL) or negative histologic findings. In these patients,
positive post-biopsy serologic findings were almost en-
tirely limited to patients who had characteristic celiac dis-
ease findings on the biopsy (Figure 3).
Discussion
Evaluation for celiac disease is one of the most common
reasons for duodenal biopsy. Positive findings in these
biopsies are relatively uncommon, despite the widespread
availability of screening assays for celiac-associated auto-
antibodies. The data presented here suggests that this is
because the vast majority of duodenal samples being sub-
mitted for “rule out celiac” are not targeted biopsies drivenites
Duodenal findings in patients with negative pre-biopsy serology
Finding N %
IVA - IEL 17 4%
Focal active inflammation 15 4%
Peptic injury 11 3%
Celiac disease 4 1%
Chronic duodenitis 3 1%
Intramucosal granulomas 2 1%
Ulcer 1 0.3%
Mild increased lymphocytes 1 0.3%
le biopsy sites. S = stomach. E = esophagus. I = ileum. C = colon. “Other gastric”





















Figure 3 Post-biopsy serologic results in patients biopsied for celiac disease. Patients are grouped into findings consistent with celiac
disease, partial villous atrophy with intraepithelial lymphocytes, or no duodenal disease detected. Positive serologic findings were rarely seen in
patients without characteristic histology. The two exceptions were both patients who had an indeterminate serology result for a single marker
(one tTG IgA, one dGDN IgA).
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site sampling strategy for a larger GI workup. In this type
of clinical application, the diagnostic yield will necessarily
be low. One limitation of the study is that because the
analysis was based on EMR results, we cannot rule out
the possibility that some patients were tested for celiac
serology prior to referral to our system. However, these
data suggest that when serologic results are available prior
to biopsy, the information can be used to guide potential
sampling strategies.
In patients with positive celiac serology results, non-
duodenal findings were present in better than half of the
patients. While many of these were non-specific changes
such as chronic gastritis, significant findings such as
lymphocytic gastritis and colitis were present in several
patients. Because these entities are more common in pa-
tients with celiac disease [23], the endoscopist may wish
to procure additional biopsies from sites such as stom-
ach and colon in patients who have a positive serologic
result prior to biopsy. In contrast, the value of duodenal
biopsy in patients with a negative pre-biopsy serology is
less clear. Histologic findings consistent with celiac dis-
ease were very uncommon in patients with negative se-
rologies. One potential limitation of this study is that the
frequency of duodenal bulb sampling was not noted,
which could potentially lead to underdiagnosis of celiac
disease in patients who were not adequately sampled. In
the four patients where villous atrophy was observed
despite a negative pre-biopsy serology, two were known
CD patients, while a third patient had collagenous sprue,
a variant of duodenal disease not associated with positiveserology [24]. The majority of duodenal findings in this
cohort were non-specific duodenitis or IVA-IEL. Based
on chart review, no patients with IVA-IEL and negative
serology were ultimately determined to have celiac dis-
ease. This suggests that in the setting of negative sero-
logic studies, duodenal biopsies rarely provide clinically
useful information that support the diagnosis of celiac
disease.
Conclusion
The decision to pursue a duodenal biopsy on a patient
involves both clinical and serological factors, and the
presence of high risk symptoms such as anemia or diar-
rhea is sufficient cause for biopsy in many published rec-
ommendations for the workup of celiac disease [25]. In
addition, some authors have advocated that duodenal bi-
opsy should routinely be performed in patients undergo-
ing endoscopy for GERD [26]. However, in lower-risk
patients the use of pre-endoscopy serology has been ad-
vocated as a tool that could optimize the decision to bi-
opsy without reducing clinical sensitivity [27]. The data
shown here support this contention, but suggest that
this approach has not been widely adopted when decid-
ing to pursue duodenal biopsy. In patients where sero-
logic data is available, the results can help in the
selection of GI locations to include in a multi-site biopsy
strategy. The expanded use of serology to screen patients
sent for endoscopy could potentially reduce the oper-
ational expenses associated with processing and evaluat-
ing large numbers of negative biopsies, resulting in more
cost-effective treatment of these patients.
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